Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation

Abstract

The editorial group responsible for this previously published document have withdrawn it from publication.

Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials

“…In addition, as with any systematic review, not all recent NMAs published were captured by the search [66,67]. Moreover, protocols are now available for several reviews and/or synthesis studies that are planned or ongoing [68][69][70], which reinforces the number of new synthesis studies in this area and therefore the importance of critically analyzing this type of evidence systematically.…”

Oral anticoagulants and clinical decision making for stroke prevention in non-valvular atrial fibrillation for nurse practitioners

“…Direct thrombin inhibitors bind to and inhibit both soluble and clot bound thrombin , which is the most potent platelet agonist (Bereznicki & Peterson, 2010;Mahtani et al, 2012). This has the advantage of preventing feedback activation of factors V, VIII, and XI (Mahtani et al).…”

“…Inhibitors of factor Xa inhibit the formation of thrombin by binding directly to its precursor (Eriksson, cited in Mahtani et al, 2012). They are able to reversibly inhibit FXa when it is present in the prothrombinase complex, as well as when it is "free" (Bereznicki & Peterson, 2010).…”

“…Therefore news of novel oral anticoagulants was received with great enthusiasm by Canadian patients with AF and their health care providers. Direct thrombin (Factor Ila) and factor Xa inhibitors, offer a solution for the inconvenience of constant blood testing and dose adjustments that was necessary with warfarin , while offering other advantages such as faster onset of action, and potentially fewer adverse interactions (Mahtani , Heneghan, & Tai , 2012).…”